Unetixs Vascular Forms Strategic Alliance with Endothelix
to Provide Earlier, Affordable Detection of Peripheral Arterial Disease

Unetixs Vascular-Endothelix alliance will extend the availability of Endothelix’s noninvasive cardiovascular diagnostics throughout Unetixs’ U.S. and international markets.

NORTH KINGSTOWN, R.I. (Oct. 14, 2009) – Thanks to a strategic alliance announced today between Unetixs Vascular and Endothelix, early warning of an impending heart attack in asymptomatic patients soon will be possible with an inexpensive, noninvasive diagnostic test performed on the same equipment as a quick, noninvasive diagnostic test for cardiovascular risk assessment and early detection of peripheral arterial disease (PAD).

Unetixs Vascular, North Kingstown, R.I., has signed an agreement with Endothelix, a Houston-based cardiovascular device company, to incorporate Endothelix’s VENDYS^® (vascular endothelial dysfunction) technology into its peripheral vascular diagnostic systems. The Unetixs systems are used widely in the United States and internationally to aid in the early diagnosis of PAD.

“Offering Endothelix’s VENDYS^® measurement technology with our highly accurate and cost-effective peripheral vascular diagnostic systems will enable primary care physicians, cardiologists and vascular specialists to improve patient care and prevent more heart attacks and strokes as well as reduce risk of amputations from PAD,” said Peter A. Moscovita, president of Unetixs Vascular Inc. “Combining the two technologies in one system will enable doctors to respond very effectively to the need for greater efficiency and economy within our healthcare systems while providing better quality care.”

According to Dr. Morteza Naghavi, founder and CEO of Endothelix, the strategic alliance with Unetixs is a significant step in commercializing the VENDYS^® measurement technology. “Our VENDYS technology has an extremely high predictive value for detection of high-risk coronary patients, and as an office-based, noninvasive system, it fills the gap between general risk factors such as high cholesterol and the advanced diagnostic structural imaging in modalities such as CT scan,” he said. “Incorporating our innovative VENDYS technology within the Unetixs’ systems makes great sense, since they cover both early and last stages of vascular disease and are highly efficient, office-based equipment widely used within the same specialties.”

###

UNP308-9/18/09-ofa